Nippon India Pharma Fund · Regular · Growth
NAV
₹569.6988
as of 31 Jul 2026
Expense Ratio
1.81%
AUM
₹8,280 Cr
Lumpsum returns (CAGR)
- 1Y
- +7.33%
- 3Y
- +18.53%
- 5Y
- +12.89%
- Since Inception
- +20.02%
SIP returns (XIRR)
- 1Y
- +19.31%
- 3Y
- +14.70%
- 5Y
- +16.98%
- Since Inception
- +18.63%
What history actually did — last 10 years (Aug 2016 – Jul 2026)
A ₹5,000 monthly SIP for the last 10 years (Aug 2016 – Jul 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,19,334 today — ₹5,95,000 invested, 18.1% XIRR.
₹5,95,000
Invested
₹15,19,334
Value today
18.1%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Aug 2016 – Jul 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹4,06,644 today (15.1% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Aug 2016 would still hold ₹25,47,105.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,19,334 in this fund vs ₹12,17,407 in the benchmark — outperformance of ₹3,01,927.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Aug 2016 – Jul 2026) (22 Mar 2020) would be ₹4,36,978 today (4.37×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.29
Sharpe Ratio
+0.06
Alpha
0.21
Beta
0.28
Sortino
13.59%
Std Dev
-10.24%
Max Drawdown
Performance Comparison
Thinking about Nippon India Pharma Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceutical Industries Limited12.78%
- 2Lupin Limited7.45%
- 3Dr. Reddy'S Laboratories Limited6.68%
- 4Cipla Limited6.15%
- 5Divi'S Laboratories Limited5.46%
- 6Apollo Hospitals Enterprise Limited5.27%
- 7Mankind Pharma Limited4.03%
- 8Sai Life Sciences Limited3.49%
- 9Ajanta Pharma Limited3.46%
- 10Max Healthcare Institute Limited3.32%
Investment Objective
Nippon India Pharma Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Nippon India Pharma Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹8,280 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.81%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations